Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Alice Burgevin"'
Publikováno v:
Clinical Case Reports, Vol 9, Iss 3, Pp 1553-1555 (2021)
Abstract When ascites fluids are observed under the microscope, unshaped greenish deposits should not be considered as artifacts but should rather prompt to bile leakage assessment.
Externí odkaz:
https://doaj.org/article/93aff42b14f24581910fcdbb37396151
Autor:
Alice Burgevin, Bénédicte Caron, Alexa Sasson, Amandine Luc, Patrick Netter, Cédric Baumann, Ashwin N. Ananthakrishnan, Laurent Peyrin-Biroulet
Publikováno v:
Journal of Clinical Medicine; Volume 11; Issue 23; Pages: 6967
Introduction: Data about the safety of vedolizumab and ustekinumab are lacking in older patients with inflammatory bowel disease. The objective was to compare the safety of vedolizumab and ustekinumab therapies in older patients (>60 years) with infl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af86919c5cc623d82842affeaf768e63
https://pubmed.ncbi.nlm.nih.gov/36498541
https://pubmed.ncbi.nlm.nih.gov/36498541
Publikováno v:
Clinical Case Reports
Clinical Case Reports, Vol 9, Iss 3, Pp 1553-1555 (2021)
Clinical Case Reports, Vol 9, Iss 3, Pp 1553-1555 (2021)
When ascites fluids are observed under the microscope, unshaped greenish deposits should not be considered as artifacts but should rather prompt to bile leakage assessment.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8c9c4a970721855b775a0cbacfeb953
http://europepmc.org/articles/PMC7981688
http://europepmc.org/articles/PMC7981688
Autor:
Alice Burgevin, Laurent Peyrin-Biroulet, Alison T. Jess, Willam Tan, Brendan Halloran, Ashwin N. Ananthakrishnan, Christopher Ma, Pei-Shun Li, Paulo Gustavo Kotze, Anne Hu, Karen I. Kroeker, Remo Panaccione
Publikováno v:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 19(7)
Background & Aims Patients with Crohn’s disease (CD) or ulcerative colitis (UC) often receive combination therapy with an immunomodulator and tumor necrosis factor antagonists, especially infliximab. However, the benefits of combination therapy wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55331a110cebf3825998f7392ba4f349
https://pubmed.ncbi.nlm.nih.gov/32668338
https://pubmed.ncbi.nlm.nih.gov/32668338